Primary Antibodies
Secondary Antibodies
Proteins & Peptides
ELISA Kits
About Us
Contact Us
Antibodies.com Logo Antibodies.com Logo
Sign In/Register
0
ISO 9001:2015 Certified
Live Customer Support
4.5/5 on Trustpilot
100% Quality Guarantee

Mk-0482 Biosimilar - Anti-LILRB4 Antibody (PE) (A334030)

Antibodies.com Image Placeholder - Discover more for less
Antibodies.com Image Placeholder - Discover more for less
Recombinant Antibody
$370
Product Datasheet

Recombinant humanized monoclonal antibody to LILRB4 (PE) for Flow Cytometry.

100% Guarantee
Price Match Guarantee
Request a Quotation
Custom or Bulk Request

Alternative Formats and ConjugatesAlternative Formats

Shipping Information

$40
Dispatched from St. Louis, MO.
Lead Time: 7-10 business days.

  • Specifications

Name
Mk-0482 Biosimilar - Anti-LILRB4 Antibody (PE)
Description
Recombinant humanized monoclonal antibody to LILRB4 (PE).
Applications
Flow Cytometry
Dilutions
Flow Cytometry: 1:100
Reactivity
Human
Host
Humanized
Clonality
Monoclonal
Isotype
IgG4
Conjugate

PE

Excitation: 565nm, Emission: 578nm

Purification
Affinity chromatography.
Concentration
Lot Specific
Product Form
Liquid
Formulation
Supplied in Phosphate Buffered Saline with 0.05% Proclin 300 and 1% BSA.
Storage
Store at 4°C. Do not freeze!
Synonyms
B4, CD85 antigen-like family member K, CD85k, ILT-3, ILT3, Immunoglobulin-like transcript 3, Leukocyte immunoglobulin-like receptor 5, Leukocyte immunoglobulin-like receptor subfamily B member 4, LIR-5, LIR5, Monocyte inhibitory receptor HM18
Disclaimer
This product is for research use only. It is not intended for diagnostic or therapeutic use.
Publishing research using Mk-0482 Biosimilar - Anti-LILRB4 Antibody (PE) (A334030)? Please let us know so that we can list the citation on this page.

Proteins predicted to interact with LILRB4

Predicted protein interactions based upon String database. Revelancy score correlates with probability of interaction.
97.6% Relevancy Score
93.4% Relevancy Score
92.4% Relevancy Score
85.9% Relevancy Score
81.3% Relevancy Score
80.7% Relevancy Score
80.7% Relevancy Score
80.6% Relevancy Score
79.5% Relevancy Score